nodes	percent_of_prediction	percent_of_DWPC	metapath
Olmesartan—ABCC2—Sorafenib—liver cancer	0.263	0.622	CbGbCtD
Olmesartan—ABCC2—Doxorubicin—liver cancer	0.159	0.378	CbGbCtD
Olmesartan—ABCC2—bile canaliculus—liver cancer	0.127	0.599	CbGeAlD
Olmesartan—ABCC2—bile duct—liver cancer	0.0396	0.187	CbGeAlD
Olmesartan—ABCC2—bile—liver cancer	0.0304	0.144	CbGeAlD
Olmesartan—Irbesartan—JUN—liver cancer	0.00572	0.564	CrCbGaD
Olmesartan—SLCO1B3—liver—liver cancer	0.00564	0.0267	CbGeAlD
Olmesartan—AGTR1—liver—liver cancer	0.00342	0.0162	CbGeAlD
Olmesartan—SLCO1B1—liver—liver cancer	0.00326	0.0154	CbGeAlD
Olmesartan—Telmisartan—PPARG—liver cancer	0.00277	0.273	CrCbGaD
Olmesartan—ABCC2—liver—liver cancer	0.00247	0.0117	CbGeAlD
Olmesartan—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00119	0.00508	CcSEcCtD
Olmesartan—Anaemia—Sorafenib—liver cancer	0.00119	0.00505	CcSEcCtD
Olmesartan—Angioedema—Sorafenib—liver cancer	0.00117	0.00499	CcSEcCtD
Olmesartan—Hyperuricaemia—Epirubicin—liver cancer	0.00117	0.00498	CcSEcCtD
Olmesartan—Syncope—Sorafenib—liver cancer	0.00115	0.0049	CcSEcCtD
Olmesartan—Leukopenia—Sorafenib—liver cancer	0.00115	0.00489	CcSEcCtD
Olmesartan—Blood bilirubin increased—Epirubicin—liver cancer	0.00115	0.00488	CcSEcCtD
Olmesartan—Jaundice cholestatic—Doxorubicin—liver cancer	0.00114	0.00486	CcSEcCtD
Olmesartan—Bone pain—Epirubicin—liver cancer	0.00113	0.00482	CcSEcCtD
Olmesartan—Loss of consciousness—Sorafenib—liver cancer	0.00113	0.0048	CcSEcCtD
Olmesartan—Cough—Sorafenib—liver cancer	0.00112	0.00477	CcSEcCtD
Olmesartan—Viral infection—Doxorubicin—liver cancer	0.00111	0.00473	CcSEcCtD
Olmesartan—Valsartan—ALB—liver cancer	0.00111	0.109	CrCbGaD
Olmesartan—Blood uric acid increased—Epirubicin—liver cancer	0.0011	0.0047	CcSEcCtD
Olmesartan—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.0011	0.0047	CcSEcCtD
Olmesartan—Myalgia—Sorafenib—liver cancer	0.00109	0.00465	CcSEcCtD
Olmesartan—Arthralgia—Sorafenib—liver cancer	0.00109	0.00465	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00108	0.00462	CcSEcCtD
Olmesartan—Hyperuricaemia—Doxorubicin—liver cancer	0.00108	0.00461	CcSEcCtD
Olmesartan—Hyperkalaemia—Epirubicin—liver cancer	0.00107	0.00454	CcSEcCtD
Olmesartan—Blood bilirubin increased—Doxorubicin—liver cancer	0.00106	0.00452	CcSEcCtD
Olmesartan—Influenza like illness—Epirubicin—liver cancer	0.00105	0.00449	CcSEcCtD
Olmesartan—Bone pain—Doxorubicin—liver cancer	0.00105	0.00446	CcSEcCtD
Olmesartan—Anaphylactic shock—Sorafenib—liver cancer	0.00105	0.00446	CcSEcCtD
Olmesartan—Infection—Sorafenib—liver cancer	0.00104	0.00443	CcSEcCtD
Olmesartan—Shock—Sorafenib—liver cancer	0.00103	0.00439	CcSEcCtD
Olmesartan—Nervous system disorder—Sorafenib—liver cancer	0.00103	0.00437	CcSEcCtD
Olmesartan—Thrombocytopenia—Sorafenib—liver cancer	0.00103	0.00437	CcSEcCtD
Olmesartan—Blood urea increased—Epirubicin—liver cancer	0.00102	0.00436	CcSEcCtD
Olmesartan—Blood uric acid increased—Doxorubicin—liver cancer	0.00102	0.00435	CcSEcCtD
Olmesartan—Aplastic anaemia—Epirubicin—liver cancer	0.00102	0.00434	CcSEcCtD
Olmesartan—Skin disorder—Sorafenib—liver cancer	0.00102	0.00433	CcSEcCtD
Olmesartan—Anorexia—Sorafenib—liver cancer	0.000998	0.00425	CcSEcCtD
Olmesartan—Hyperkalaemia—Doxorubicin—liver cancer	0.000986	0.0042	CcSEcCtD
Olmesartan—Influenza like illness—Doxorubicin—liver cancer	0.000974	0.00415	CcSEcCtD
Olmesartan—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000954	0.00406	CcSEcCtD
Olmesartan—Blood urea increased—Doxorubicin—liver cancer	0.000947	0.00403	CcSEcCtD
Olmesartan—Aplastic anaemia—Doxorubicin—liver cancer	0.000942	0.00401	CcSEcCtD
Olmesartan—Dyspepsia—Sorafenib—liver cancer	0.000922	0.00393	CcSEcCtD
Olmesartan—Decreased appetite—Sorafenib—liver cancer	0.00091	0.00388	CcSEcCtD
Olmesartan—Diabetes mellitus—Epirubicin—liver cancer	0.000905	0.00385	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Sorafenib—liver cancer	0.000904	0.00385	CcSEcCtD
Olmesartan—Fatigue—Sorafenib—liver cancer	0.000903	0.00384	CcSEcCtD
Olmesartan—Constipation—Sorafenib—liver cancer	0.000895	0.00381	CcSEcCtD
Olmesartan—Pain—Sorafenib—liver cancer	0.000895	0.00381	CcSEcCtD
Olmesartan—Eczema—Epirubicin—liver cancer	0.000876	0.00373	CcSEcCtD
Olmesartan—Gastrointestinal pain—Sorafenib—liver cancer	0.000856	0.00365	CcSEcCtD
Olmesartan—Renal failure acute—Epirubicin—liver cancer	0.000853	0.00363	CcSEcCtD
Olmesartan—Diabetes mellitus—Doxorubicin—liver cancer	0.000837	0.00357	CcSEcCtD
Olmesartan—Urticaria—Sorafenib—liver cancer	0.000832	0.00354	CcSEcCtD
Olmesartan—Abdominal pain—Sorafenib—liver cancer	0.000828	0.00353	CcSEcCtD
Olmesartan—Body temperature increased—Sorafenib—liver cancer	0.000828	0.00353	CcSEcCtD
Olmesartan—Eczema—Doxorubicin—liver cancer	0.000811	0.00345	CcSEcCtD
Olmesartan—Lethargy—Epirubicin—liver cancer	0.000803	0.00342	CcSEcCtD
Olmesartan—Hyponatraemia—Epirubicin—liver cancer	0.00079	0.00337	CcSEcCtD
Olmesartan—Renal failure acute—Doxorubicin—liver cancer	0.000789	0.00336	CcSEcCtD
Olmesartan—Pain in extremity—Epirubicin—liver cancer	0.000787	0.00335	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—TRIO—liver cancer	0.000777	0.00638	CbGpPWpGaD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.000768	0.00631	CbGpPWpGaD
Olmesartan—Face oedema—Epirubicin—liver cancer	0.00076	0.00324	CcSEcCtD
Olmesartan—Asthenia—Sorafenib—liver cancer	0.000751	0.0032	CcSEcCtD
Olmesartan—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000751	0.00616	CbGpPWpGaD
Olmesartan—Lethargy—Doxorubicin—liver cancer	0.000743	0.00317	CcSEcCtD
Olmesartan—Pruritus—Sorafenib—liver cancer	0.000741	0.00315	CcSEcCtD
Olmesartan—Blood creatinine increased—Epirubicin—liver cancer	0.000737	0.00314	CcSEcCtD
Olmesartan—Hyponatraemia—Doxorubicin—liver cancer	0.000731	0.00311	CcSEcCtD
Olmesartan—Pain in extremity—Doxorubicin—liver cancer	0.000728	0.0031	CcSEcCtD
Olmesartan—Orthostatic hypotension—Epirubicin—liver cancer	0.000719	0.00306	CcSEcCtD
Olmesartan—Hypokalaemia—Epirubicin—liver cancer	0.000716	0.00305	CcSEcCtD
Olmesartan—Diarrhoea—Sorafenib—liver cancer	0.000716	0.00305	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—GSTA4—liver cancer	0.000711	0.00584	CbGpPWpGaD
Olmesartan—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000709	0.00302	CcSEcCtD
Olmesartan—Toxic epidermal necrolysis—Epirubicin—liver cancer	0.000709	0.00302	CcSEcCtD
Olmesartan—Nasopharyngitis—Epirubicin—liver cancer	0.000704	0.003	CcSEcCtD
Olmesartan—Face oedema—Doxorubicin—liver cancer	0.000703	0.003	CcSEcCtD
Olmesartan—Alanine aminotransferase increased—Epirubicin—liver cancer	0.000694	0.00296	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—GSTA2—liver cancer	0.000693	0.00569	CbGpPWpGaD
Olmesartan—Dizziness—Sorafenib—liver cancer	0.000692	0.00295	CcSEcCtD
Olmesartan—Blood creatinine increased—Doxorubicin—liver cancer	0.000682	0.00291	CcSEcCtD
Olmesartan—Influenza—Epirubicin—liver cancer	0.00068	0.0029	CcSEcCtD
Olmesartan—Eosinophilia—Epirubicin—liver cancer	0.000674	0.00287	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—GSTA1—liver cancer	0.000668	0.00549	CbGpPWpGaD
Olmesartan—Pancreatitis—Epirubicin—liver cancer	0.000667	0.00284	CcSEcCtD
Olmesartan—Vomiting—Sorafenib—liver cancer	0.000666	0.00284	CcSEcCtD
Olmesartan—Orthostatic hypotension—Doxorubicin—liver cancer	0.000665	0.00283	CcSEcCtD
Olmesartan—Hypokalaemia—Doxorubicin—liver cancer	0.000663	0.00282	CcSEcCtD
Olmesartan—Angina pectoris—Epirubicin—liver cancer	0.000663	0.00282	CcSEcCtD
Olmesartan—Rash—Sorafenib—liver cancer	0.00066	0.00281	CcSEcCtD
Olmesartan—Dermatitis—Sorafenib—liver cancer	0.000659	0.00281	CcSEcCtD
Olmesartan—Toxic epidermal necrolysis—Doxorubicin—liver cancer	0.000656	0.00279	CcSEcCtD
Olmesartan—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000656	0.00279	CcSEcCtD
Olmesartan—Headache—Sorafenib—liver cancer	0.000656	0.00279	CcSEcCtD
Olmesartan—Bronchitis—Epirubicin—liver cancer	0.000654	0.00279	CcSEcCtD
Olmesartan—AGTR1—Arf6 trafficking events—CTNNB1—liver cancer	0.000653	0.00536	CbGpPWpGaD
Olmesartan—Nasopharyngitis—Doxorubicin—liver cancer	0.000651	0.00277	CcSEcCtD
Olmesartan—Pancytopenia—Epirubicin—liver cancer	0.000646	0.00275	CcSEcCtD
Olmesartan—AGTR1—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.000644	0.00528	CbGpPWpGaD
Olmesartan—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000642	0.00274	CcSEcCtD
Olmesartan—Neutropenia—Epirubicin—liver cancer	0.000636	0.00271	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Epirubicin—liver cancer	0.000632	0.00269	CcSEcCtD
Olmesartan—Influenza—Doxorubicin—liver cancer	0.00063	0.00268	CcSEcCtD
Olmesartan—Eosinophilia—Doxorubicin—liver cancer	0.000623	0.00265	CcSEcCtD
Olmesartan—Nausea—Sorafenib—liver cancer	0.000622	0.00265	CcSEcCtD
Olmesartan—Photosensitivity reaction—Epirubicin—liver cancer	0.000621	0.00265	CcSEcCtD
Olmesartan—Pancreatitis—Doxorubicin—liver cancer	0.000617	0.00263	CcSEcCtD
Olmesartan—Hyperglycaemia—Epirubicin—liver cancer	0.000614	0.00261	CcSEcCtD
Olmesartan—Angina pectoris—Doxorubicin—liver cancer	0.000613	0.00261	CcSEcCtD
Olmesartan—Pneumonia—Epirubicin—liver cancer	0.00061	0.0026	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—CDKN1A—liver cancer	0.000607	0.00499	CbGpPWpGaD
Olmesartan—Infestation NOS—Epirubicin—liver cancer	0.000607	0.00258	CcSEcCtD
Olmesartan—Infestation—Epirubicin—liver cancer	0.000607	0.00258	CcSEcCtD
Olmesartan—SLCO1B1—Bile acid and bile salt metabolism—ALB—liver cancer	0.000606	0.00497	CbGpPWpGaD
Olmesartan—Bronchitis—Doxorubicin—liver cancer	0.000605	0.00258	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000599	0.00492	CbGpPWpGaD
Olmesartan—Pancytopenia—Doxorubicin—liver cancer	0.000598	0.00255	CcSEcCtD
Olmesartan—Renal failure—Epirubicin—liver cancer	0.000596	0.00254	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—MAPK8—liver cancer	0.000593	0.00487	CbGpPWpGaD
Olmesartan—Jaundice—Epirubicin—liver cancer	0.000591	0.00252	CcSEcCtD
Olmesartan—Urinary tract infection—Epirubicin—liver cancer	0.00059	0.00251	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—NFE2L2—liver cancer	0.000589	0.00484	CbGpPWpGaD
Olmesartan—Neutropenia—Doxorubicin—liver cancer	0.000589	0.00251	CcSEcCtD
Olmesartan—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000585	0.00249	CcSEcCtD
Olmesartan—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—liver cancer	0.00058	0.00476	CbGpPWpGaD
Olmesartan—Haematuria—Epirubicin—liver cancer	0.000578	0.00246	CcSEcCtD
Olmesartan—Photosensitivity reaction—Doxorubicin—liver cancer	0.000575	0.00245	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000572	0.0047	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000572	0.0047	CbGpPWpGaD
Olmesartan—Sinusitis—Epirubicin—liver cancer	0.000569	0.00242	CcSEcCtD
Olmesartan—Hyperglycaemia—Doxorubicin—liver cancer	0.000568	0.00242	CcSEcCtD
Olmesartan—Agranulocytosis—Epirubicin—liver cancer	0.000566	0.00241	CcSEcCtD
Olmesartan—Pneumonia—Doxorubicin—liver cancer	0.000565	0.0024	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—GPX3—liver cancer	0.000562	0.00461	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—TGFA—liver cancer	0.000562	0.00461	CbGpPWpGaD
Olmesartan—Infestation—Doxorubicin—liver cancer	0.000561	0.00239	CcSEcCtD
Olmesartan—Infestation NOS—Doxorubicin—liver cancer	0.000561	0.00239	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—SERPINA1—liver cancer	0.000554	0.00455	CbGpPWpGaD
Olmesartan—Renal failure—Doxorubicin—liver cancer	0.000552	0.00235	CcSEcCtD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.000552	0.00453	CbGpPWpGaD
Olmesartan—Jaundice—Doxorubicin—liver cancer	0.000547	0.00233	CcSEcCtD
Olmesartan—Rhinitis—Epirubicin—liver cancer	0.000546	0.00233	CcSEcCtD
Olmesartan—Urinary tract infection—Doxorubicin—liver cancer	0.000546	0.00232	CcSEcCtD
Olmesartan—Losartan—ALB—liver cancer	0.000541	0.0534	CrCbGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC11A2—liver cancer	0.000541	0.00444	CbGpPWpGaD
Olmesartan—Pharyngitis—Epirubicin—liver cancer	0.000541	0.0023	CcSEcCtD
Olmesartan—Urinary tract disorder—Epirubicin—liver cancer	0.000538	0.00229	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC9C1—liver cancer	0.000537	0.00441	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—MYO5B—liver cancer	0.000537	0.00441	CbGpPWpGaD
Olmesartan—Oedema peripheral—Epirubicin—liver cancer	0.000536	0.00229	CcSEcCtD
Olmesartan—Haematuria—Doxorubicin—liver cancer	0.000535	0.00228	CcSEcCtD
Olmesartan—Connective tissue disorder—Epirubicin—liver cancer	0.000535	0.00228	CcSEcCtD
Olmesartan—Urethral disorder—Epirubicin—liver cancer	0.000534	0.00227	CcSEcCtD
Olmesartan—Sinusitis—Doxorubicin—liver cancer	0.000527	0.00224	CcSEcCtD
Olmesartan—Agranulocytosis—Doxorubicin—liver cancer	0.000524	0.00223	CcSEcCtD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—SLC40A1—liver cancer	0.000516	0.00424	CbGpPWpGaD
Olmesartan—Rhinitis—Doxorubicin—liver cancer	0.000505	0.00215	CcSEcCtD
Olmesartan—Pharyngitis—Doxorubicin—liver cancer	0.0005	0.00213	CcSEcCtD
Olmesartan—Urinary tract disorder—Doxorubicin—liver cancer	0.000498	0.00212	CcSEcCtD
Olmesartan—Oedema peripheral—Doxorubicin—liver cancer	0.000496	0.00211	CcSEcCtD
Olmesartan—Connective tissue disorder—Doxorubicin—liver cancer	0.000495	0.00211	CcSEcCtD
Olmesartan—Angiopathy—Epirubicin—liver cancer	0.000494	0.0021	CcSEcCtD
Olmesartan—Urethral disorder—Doxorubicin—liver cancer	0.000494	0.0021	CcSEcCtD
Olmesartan—Mediastinal disorder—Epirubicin—liver cancer	0.000491	0.00209	CcSEcCtD
Olmesartan—Arrhythmia—Epirubicin—liver cancer	0.000487	0.00207	CcSEcCtD
Olmesartan—Alopecia—Epirubicin—liver cancer	0.000481	0.00205	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—PRKCE—liver cancer	0.00048	0.00394	CbGpPWpGaD
Olmesartan—Mental disorder—Epirubicin—liver cancer	0.000477	0.00203	CcSEcCtD
Olmesartan—Malnutrition—Epirubicin—liver cancer	0.000474	0.00202	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—liver cancer	0.000469	0.00385	CbGpPWpGaD
Olmesartan—Back pain—Epirubicin—liver cancer	0.000459	0.00195	CcSEcCtD
Olmesartan—Angiopathy—Doxorubicin—liver cancer	0.000457	0.00195	CcSEcCtD
Olmesartan—Muscle spasms—Epirubicin—liver cancer	0.000456	0.00194	CcSEcCtD
Olmesartan—Mediastinal disorder—Doxorubicin—liver cancer	0.000454	0.00193	CcSEcCtD
Olmesartan—Arrhythmia—Doxorubicin—liver cancer	0.00045	0.00192	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—CASP3—liver cancer	0.000447	0.00367	CbGpPWpGaD
Olmesartan—Vision blurred—Epirubicin—liver cancer	0.000447	0.0019	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—IL2—liver cancer	0.000447	0.00367	CbGpPWpGaD
Olmesartan—Alopecia—Doxorubicin—liver cancer	0.000445	0.0019	CcSEcCtD
Olmesartan—Mental disorder—Doxorubicin—liver cancer	0.000441	0.00188	CcSEcCtD
Olmesartan—Ill-defined disorder—Epirubicin—liver cancer	0.00044	0.00187	CcSEcCtD
Olmesartan—Malnutrition—Doxorubicin—liver cancer	0.000439	0.00187	CcSEcCtD
Olmesartan—Anaemia—Epirubicin—liver cancer	0.000438	0.00187	CcSEcCtD
Olmesartan—Agitation—Epirubicin—liver cancer	0.000436	0.00186	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCE—liver cancer	0.000429	0.00352	CbGpPWpGaD
Olmesartan—Malaise—Epirubicin—liver cancer	0.000428	0.00182	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—PIK3CA—liver cancer	0.000427	0.00351	CbGpPWpGaD
Olmesartan—Vertigo—Epirubicin—liver cancer	0.000426	0.00181	CcSEcCtD
Olmesartan—Syncope—Epirubicin—liver cancer	0.000425	0.00181	CcSEcCtD
Olmesartan—Leukopenia—Epirubicin—liver cancer	0.000424	0.00181	CcSEcCtD
Olmesartan—Back pain—Doxorubicin—liver cancer	0.000424	0.00181	CcSEcCtD
Olmesartan—Muscle spasms—Doxorubicin—liver cancer	0.000422	0.0018	CcSEcCtD
Olmesartan—AGTR1—GPCR ligand binding—CCR4—liver cancer	0.00042	0.00345	CbGpPWpGaD
Olmesartan—Palpitations—Epirubicin—liver cancer	0.000419	0.00178	CcSEcCtD
Olmesartan—Loss of consciousness—Epirubicin—liver cancer	0.000417	0.00177	CcSEcCtD
Olmesartan—Cough—Epirubicin—liver cancer	0.000414	0.00176	CcSEcCtD
Olmesartan—Vision blurred—Doxorubicin—liver cancer	0.000413	0.00176	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000409	0.00336	CbGpPWpGaD
Olmesartan—Ill-defined disorder—Doxorubicin—liver cancer	0.000407	0.00173	CcSEcCtD
Olmesartan—Anaemia—Doxorubicin—liver cancer	0.000405	0.00173	CcSEcCtD
Olmesartan—Chest pain—Epirubicin—liver cancer	0.000404	0.00172	CcSEcCtD
Olmesartan—Arthralgia—Epirubicin—liver cancer	0.000404	0.00172	CcSEcCtD
Olmesartan—Myalgia—Epirubicin—liver cancer	0.000404	0.00172	CcSEcCtD
Olmesartan—Agitation—Doxorubicin—liver cancer	0.000403	0.00172	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000403	0.0033	CbGpPWpGaD
Olmesartan—Anxiety—Epirubicin—liver cancer	0.000402	0.00171	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000401	0.00171	CcSEcCtD
Olmesartan—Discomfort—Epirubicin—liver cancer	0.000399	0.0017	CcSEcCtD
Olmesartan—Malaise—Doxorubicin—liver cancer	0.000396	0.00168	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—GGT1—liver cancer	0.000395	0.00325	CbGpPWpGaD
Olmesartan—Vertigo—Doxorubicin—liver cancer	0.000394	0.00168	CcSEcCtD
Olmesartan—Syncope—Doxorubicin—liver cancer	0.000393	0.00168	CcSEcCtD
Olmesartan—Leukopenia—Doxorubicin—liver cancer	0.000393	0.00167	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.00039	0.00321	CbGpPWpGaD
Olmesartan—Palpitations—Doxorubicin—liver cancer	0.000388	0.00165	CcSEcCtD
Olmesartan—Oedema—Epirubicin—liver cancer	0.000387	0.00165	CcSEcCtD
Olmesartan—Anaphylactic shock—Epirubicin—liver cancer	0.000387	0.00165	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000386	0.00317	CbGpPWpGaD
Olmesartan—Loss of consciousness—Doxorubicin—liver cancer	0.000386	0.00164	CcSEcCtD
Olmesartan—Infection—Epirubicin—liver cancer	0.000384	0.00164	CcSEcCtD
Olmesartan—Cough—Doxorubicin—liver cancer	0.000383	0.00163	CcSEcCtD
Olmesartan—Shock—Epirubicin—liver cancer	0.000381	0.00162	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—VEGFA—liver cancer	0.00038	0.00312	CbGpPWpGaD
Olmesartan—Nervous system disorder—Epirubicin—liver cancer	0.000379	0.00162	CcSEcCtD
Olmesartan—Thrombocytopenia—Epirubicin—liver cancer	0.000379	0.00161	CcSEcCtD
Olmesartan—Tachycardia—Epirubicin—liver cancer	0.000378	0.00161	CcSEcCtD
Olmesartan—Skin disorder—Epirubicin—liver cancer	0.000376	0.0016	CcSEcCtD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000374	0.00307	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000374	0.00307	CbGpPWpGaD
Olmesartan—Hyperhidrosis—Epirubicin—liver cancer	0.000374	0.00159	CcSEcCtD
Olmesartan—Arthralgia—Doxorubicin—liver cancer	0.000373	0.00159	CcSEcCtD
Olmesartan—Chest pain—Doxorubicin—liver cancer	0.000373	0.00159	CcSEcCtD
Olmesartan—Myalgia—Doxorubicin—liver cancer	0.000373	0.00159	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000372	0.00306	CbGpPWpGaD
Olmesartan—Anxiety—Doxorubicin—liver cancer	0.000372	0.00159	CcSEcCtD
Olmesartan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000371	0.00158	CcSEcCtD
Olmesartan—Discomfort—Doxorubicin—liver cancer	0.000369	0.00157	CcSEcCtD
Olmesartan—Anorexia—Epirubicin—liver cancer	0.000369	0.00157	CcSEcCtD
Olmesartan—Hypotension—Epirubicin—liver cancer	0.000362	0.00154	CcSEcCtD
Olmesartan—Anaphylactic shock—Doxorubicin—liver cancer	0.000358	0.00152	CcSEcCtD
Olmesartan—Oedema—Doxorubicin—liver cancer	0.000358	0.00152	CcSEcCtD
Olmesartan—Infection—Doxorubicin—liver cancer	0.000356	0.00151	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—GSTP1—liver cancer	0.000355	0.00292	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000354	0.00291	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000353	0.0015	CcSEcCtD
Olmesartan—Shock—Doxorubicin—liver cancer	0.000352	0.0015	CcSEcCtD
Olmesartan—Nervous system disorder—Doxorubicin—liver cancer	0.000351	0.0015	CcSEcCtD
Olmesartan—Thrombocytopenia—Doxorubicin—liver cancer	0.000351	0.00149	CcSEcCtD
Olmesartan—ABCC2—NRF2 pathway—HMOX1—liver cancer	0.00035	0.00288	CbGpPWpGaD
Olmesartan—Insomnia—Epirubicin—liver cancer	0.00035	0.00149	CcSEcCtD
Olmesartan—Tachycardia—Doxorubicin—liver cancer	0.000349	0.00149	CcSEcCtD
Olmesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—AKT1—liver cancer	0.000349	0.00287	CbGpPWpGaD
Olmesartan—AGTR1—Allograft Rejection—TGFB1—liver cancer	0.000348	0.00286	CbGpPWpGaD
Olmesartan—Skin disorder—Doxorubicin—liver cancer	0.000348	0.00148	CcSEcCtD
Olmesartan—Hyperhidrosis—Doxorubicin—liver cancer	0.000346	0.00147	CcSEcCtD
Olmesartan—Anorexia—Doxorubicin—liver cancer	0.000341	0.00145	CcSEcCtD
Olmesartan—Dyspepsia—Epirubicin—liver cancer	0.000341	0.00145	CcSEcCtD
Olmesartan—Decreased appetite—Epirubicin—liver cancer	0.000336	0.00143	CcSEcCtD
Olmesartan—Hypotension—Doxorubicin—liver cancer	0.000335	0.00142	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Epirubicin—liver cancer	0.000334	0.00142	CcSEcCtD
Olmesartan—Fatigue—Epirubicin—liver cancer	0.000334	0.00142	CcSEcCtD
Olmesartan—AGTR1—G alpha (q) signalling events—F2—liver cancer	0.000333	0.00273	CbGpPWpGaD
Olmesartan—Pain—Epirubicin—liver cancer	0.000331	0.00141	CcSEcCtD
Olmesartan—Constipation—Epirubicin—liver cancer	0.000331	0.00141	CcSEcCtD
Olmesartan—AGTR1—Peptide ligand-binding receptors—F2—liver cancer	0.000329	0.0027	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—GSTM1—liver cancer	0.000326	0.00268	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—HGF—liver cancer	0.000326	0.00268	CbGpPWpGaD
Olmesartan—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.000326	0.00139	CcSEcCtD
Olmesartan—AGTR1—Allograft Rejection—TNF—liver cancer	0.000325	0.00267	CbGpPWpGaD
Olmesartan—Insomnia—Doxorubicin—liver cancer	0.000324	0.00138	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—CHN2—liver cancer	0.00032	0.00263	CbGpPWpGaD
Olmesartan—Feeling abnormal—Epirubicin—liver cancer	0.000319	0.00136	CcSEcCtD
Olmesartan—Gastrointestinal pain—Epirubicin—liver cancer	0.000316	0.00135	CcSEcCtD
Olmesartan—Dyspepsia—Doxorubicin—liver cancer	0.000315	0.00134	CcSEcCtD
Olmesartan—Decreased appetite—Doxorubicin—liver cancer	0.000311	0.00133	CcSEcCtD
Olmesartan—Gastrointestinal disorder—Doxorubicin—liver cancer	0.000309	0.00132	CcSEcCtD
Olmesartan—Fatigue—Doxorubicin—liver cancer	0.000309	0.00131	CcSEcCtD
Olmesartan—Urticaria—Epirubicin—liver cancer	0.000307	0.00131	CcSEcCtD
Olmesartan—Pain—Doxorubicin—liver cancer	0.000306	0.0013	CcSEcCtD
Olmesartan—Constipation—Doxorubicin—liver cancer	0.000306	0.0013	CcSEcCtD
Olmesartan—Abdominal pain—Epirubicin—liver cancer	0.000306	0.0013	CcSEcCtD
Olmesartan—Body temperature increased—Epirubicin—liver cancer	0.000306	0.0013	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—liver cancer	0.000298	0.00244	CbGpPWpGaD
Olmesartan—Feeling abnormal—Doxorubicin—liver cancer	0.000295	0.00126	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000293	0.0024	CbGpPWpGaD
Olmesartan—Gastrointestinal pain—Doxorubicin—liver cancer	0.000293	0.00125	CcSEcCtD
Olmesartan—AGTR1—Signaling Pathways—IFT88—liver cancer	0.000293	0.0024	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000285	0.00234	CbGpPWpGaD
Olmesartan—Urticaria—Doxorubicin—liver cancer	0.000284	0.00121	CcSEcCtD
Olmesartan—SLCO1B3—Metabolism—UGDH—liver cancer	0.000284	0.00233	CbGpPWpGaD
Olmesartan—Abdominal pain—Doxorubicin—liver cancer	0.000283	0.00121	CcSEcCtD
Olmesartan—Body temperature increased—Doxorubicin—liver cancer	0.000283	0.00121	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000279	0.00229	CbGpPWpGaD
Olmesartan—Asthenia—Epirubicin—liver cancer	0.000278	0.00118	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC11A2—liver cancer	0.000275	0.00226	CbGpPWpGaD
Olmesartan—Pruritus—Epirubicin—liver cancer	0.000274	0.00117	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000268	0.0022	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000268	0.0022	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—EPT1—liver cancer	0.000267	0.00219	CbGpPWpGaD
Olmesartan—Diarrhoea—Epirubicin—liver cancer	0.000265	0.00113	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—SLC40A1—liver cancer	0.000262	0.00215	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000259	0.00213	CbGpPWpGaD
Olmesartan—Asthenia—Doxorubicin—liver cancer	0.000257	0.00109	CcSEcCtD
Olmesartan—Dizziness—Epirubicin—liver cancer	0.000256	0.00109	CcSEcCtD
Olmesartan—Pruritus—Doxorubicin—liver cancer	0.000253	0.00108	CcSEcCtD
Olmesartan—ABCC2—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000253	0.00208	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—TAT—liver cancer	0.000253	0.00208	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ATP7B—liver cancer	0.000252	0.00206	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ANXA2—liver cancer	0.000252	0.00206	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.00025	0.00205	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000249	0.00204	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—TRIO—liver cancer	0.000248	0.00203	CbGpPWpGaD
Olmesartan—Vomiting—Epirubicin—liver cancer	0.000246	0.00105	CcSEcCtD
Olmesartan—Diarrhoea—Doxorubicin—liver cancer	0.000245	0.00104	CcSEcCtD
Olmesartan—Rash—Epirubicin—liver cancer	0.000244	0.00104	CcSEcCtD
Olmesartan—Dermatitis—Epirubicin—liver cancer	0.000244	0.00104	CcSEcCtD
Olmesartan—Headache—Epirubicin—liver cancer	0.000242	0.00103	CcSEcCtD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—NR1H4—liver cancer	0.000238	0.00195	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CCR4—liver cancer	0.000237	0.00195	CbGpPWpGaD
Olmesartan—Dizziness—Doxorubicin—liver cancer	0.000237	0.00101	CcSEcCtD
Olmesartan—Nausea—Epirubicin—liver cancer	0.00023	0.000979	CcSEcCtD
Olmesartan—Vomiting—Doxorubicin—liver cancer	0.000228	0.000969	CcSEcCtD
Olmesartan—Rash—Doxorubicin—liver cancer	0.000226	0.000961	CcSEcCtD
Olmesartan—Dermatitis—Doxorubicin—liver cancer	0.000226	0.000961	CcSEcCtD
Olmesartan—AGTR1—Signaling by GPCR—TRIO—liver cancer	0.000225	0.00185	CbGpPWpGaD
Olmesartan—Headache—Doxorubicin—liver cancer	0.000224	0.000955	CcSEcCtD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—liver cancer	0.000224	0.00184	CbGpPWpGaD
Olmesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.00022	0.00181	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CCR4—liver cancer	0.000216	0.00177	CbGpPWpGaD
Olmesartan—Nausea—Doxorubicin—liver cancer	0.000213	0.000906	CcSEcCtD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000191	0.00157	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—UGDH—liver cancer	0.000191	0.00157	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000186	0.00153	CbGpPWpGaD
Olmesartan—SLCO1B3—SLC-mediated transmembrane transport—ALB—liver cancer	0.000185	0.00152	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—CYCS—liver cancer	0.00018	0.00148	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SHC3—liver cancer	0.000179	0.00147	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—EPT1—liver cancer	0.000179	0.00147	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CPT1B—liver cancer	0.000172	0.00141	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GLUL—liver cancer	0.000172	0.00141	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—TAT—liver cancer	0.00017	0.0014	CbGpPWpGaD
Olmesartan—AGTR1—GPCR ligand binding—F2—liver cancer	0.000168	0.00138	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000167	0.00137	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NR1H4—liver cancer	0.000166	0.00136	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTA3—liver cancer	0.000163	0.00134	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000157	0.00129	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTA4—liver cancer	0.000149	0.00122	CbGpPWpGaD
Olmesartan—AGTR1—G alpha (q) signalling events—PIK3CA—liver cancer	0.000149	0.00122	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.000146	0.0012	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTA2—liver cancer	0.000145	0.00119	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.000145	0.00119	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTA1—liver cancer	0.00014	0.00115	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—FST—liver cancer	0.000139	0.00114	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—NAT2—liver cancer	0.000139	0.00114	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PRKCE—liver cancer	0.000137	0.00112	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.000133	0.00109	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	0.000133	0.00109	CbGpPWpGaD
Olmesartan—ABCC2—NRF2 pathway—TGFB1—liver cancer	0.000133	0.00109	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALDOB—liver cancer	0.000133	0.00109	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TRIO—liver cancer	0.000133	0.00109	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—CYCS—liver cancer	0.000129	0.00106	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCR4—liver cancer	0.000127	0.00105	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CRABP1—liver cancer	0.000127	0.00104	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—PPARA—liver cancer	0.000127	0.00104	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.000125	0.00103	CbGpPWpGaD
Olmesartan—SLCO1B1—SLC-mediated transmembrane transport—ALB—liver cancer	0.000125	0.00102	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PRKCE—liver cancer	0.000124	0.00102	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	0.000123	0.00101	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—CYCS—liver cancer	0.000121	0.000995	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—CSF2—liver cancer	0.000121	0.000993	CbGpPWpGaD
Olmesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	0.000118	0.000967	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CPT1B—liver cancer	0.000116	0.000948	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GLUL—liver cancer	0.000116	0.000948	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	0.000114	0.000937	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000112	0.000921	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NR1H4—liver cancer	0.000111	0.000914	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—HPGDS—liver cancer	0.000111	0.00091	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PPARG—liver cancer	0.00011	0.000904	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—CSF2—liver cancer	0.00011	0.000901	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTA3—liver cancer	0.00011	0.000899	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—HMOX1—liver cancer	0.000105	0.000865	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ADAM17—liver cancer	0.000101	0.000826	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	0.0001	0.000824	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTA4—liver cancer	0.0001	0.000822	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—ALB—liver cancer	9.9e-05	0.000813	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PSMD10—liver cancer	9.88e-05	0.000811	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PSMA4—liver cancer	9.88e-05	0.000811	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	9.79e-05	0.000804	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTA2—liver cancer	9.76e-05	0.000801	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GOT2—liver cancer	9.61e-05	0.000789	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—F2—liver cancer	9.49e-05	0.000779	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PSMA4—liver cancer	9.46e-05	0.000777	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PSMD10—liver cancer	9.46e-05	0.000777	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—ALB—liver cancer	9.42e-05	0.000773	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTA1—liver cancer	9.42e-05	0.000773	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—NAT2—liver cancer	9.31e-05	0.000764	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CG—liver cancer	9.08e-05	0.000745	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—PPARA—liver cancer	9.06e-05	0.000744	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP2E1—liver cancer	9.03e-05	0.000741	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARA—liver cancer	8.95e-05	0.000735	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALDOB—liver cancer	8.93e-05	0.000733	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	8.75e-05	0.000718	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—F2—liver cancer	8.62e-05	0.000707	CbGpPWpGaD
Olmesartan—SLCO1B3—Transmembrane transport of small molecules—RAF1—liver cancer	8.52e-05	0.000699	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CRABP1—liver cancer	8.52e-05	0.000699	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—PPARA—liver cancer	8.51e-05	0.000699	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYCS—liver cancer	8.45e-05	0.000694	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GGT1—liver cancer	8.29e-05	0.000681	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GOT1—liver cancer	8.29e-05	0.000681	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CG—liver cancer	8.25e-05	0.000677	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CD—liver cancer	7.98e-05	0.000655	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	7.67e-05	0.000629	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTP1—liver cancer	7.45e-05	0.000611	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—HPGDS—liver cancer	7.44e-05	0.000611	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PPARG—liver cancer	7.4e-05	0.000608	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—HMOX1—liver cancer	7.35e-05	0.000603	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PRKCE—liver cancer	7.33e-05	0.000602	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CD—liver cancer	7.25e-05	0.000595	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CB—liver cancer	6.96e-05	0.000571	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IGF2—liver cancer	6.95e-05	0.00057	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—GSTM1—liver cancer	6.85e-05	0.000562	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	6.74e-05	0.000553	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—ALB—liver cancer	6.74e-05	0.000553	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—liver cancer	6.65e-05	0.000546	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PSMD10—liver cancer	6.63e-05	0.000545	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PSMA4—liver cancer	6.63e-05	0.000545	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—CYP1A1—liver cancer	6.49e-05	0.000533	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CSF2—liver cancer	6.49e-05	0.000532	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—RAF1—liver cancer	6.47e-05	0.000531	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GOT2—liver cancer	6.45e-05	0.00053	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—H2AFX—liver cancer	6.39e-05	0.000525	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—IL2—liver cancer	6.39e-05	0.000525	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—ALB—liver cancer	6.33e-05	0.000519	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CB—liver cancer	6.32e-05	0.000519	CbGpPWpGaD
Olmesartan—ABCC2—Transmembrane transport of small molecules—RAF1—liver cancer	6.09e-05	0.0005	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP2E1—liver cancer	6.07e-05	0.000498	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—MTHFR—liver cancer	6.05e-05	0.000497	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PPARA—liver cancer	5.93e-05	0.000487	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	5.88e-05	0.000482	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL2—liver cancer	5.8e-05	0.000476	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TERT—liver cancer	5.78e-05	0.000475	CbGpPWpGaD
Olmesartan—SLCO1B1—Transmembrane transport of small molecules—RAF1—liver cancer	5.72e-05	0.00047	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYCS—liver cancer	5.68e-05	0.000466	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GOT1—liver cancer	5.57e-05	0.000457	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GGT1—liver cancer	5.57e-05	0.000457	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	5.33e-05	0.000438	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KDR—liver cancer	5.29e-05	0.000434	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MAPK14—liver cancer	5.25e-05	0.000431	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—ESR1—liver cancer	5.15e-05	0.000423	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—F2—liver cancer	5.09e-05	0.000418	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CG—liver cancer	5.08e-05	0.000417	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTP1—liver cancer	5e-05	0.000411	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—HMOX1—liver cancer	4.94e-05	0.000405	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PPARG—liver cancer	4.91e-05	0.000403	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—APC—liver cancer	4.87e-05	0.0004	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CG—liver cancer	4.87e-05	0.0004	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—GSTM1—liver cancer	4.6e-05	0.000378	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—BRAF—liver cancer	4.58e-05	0.000376	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CD—liver cancer	4.47e-05	0.000367	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—ALB—liver cancer	4.41e-05	0.000362	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—CYP1A1—liver cancer	4.36e-05	0.000358	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CD—liver cancer	4.28e-05	0.000352	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—PIK3CA—liver cancer	4.24e-05	0.000348	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—SERPINE1—liver cancer	4.23e-05	0.000348	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—KRAS—liver cancer	4.19e-05	0.000344	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—MTHFR—liver cancer	4.06e-05	0.000334	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PPARA—liver cancer	3.99e-05	0.000327	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CB—liver cancer	3.89e-05	0.00032	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—PIK3CA—liver cancer	3.85e-05	0.000316	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—RAF1—liver cancer	3.82e-05	0.000314	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MTOR—liver cancer	3.73e-05	0.000306	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CB—liver cancer	3.73e-05	0.000306	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	3.58e-05	0.000294	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—HRAS—liver cancer	3.56e-05	0.000293	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CDKN1B—liver cancer	3.5e-05	0.000288	CbGpPWpGaD
Olmesartan—AGTR1—GPCR downstream signaling—AKT1—liver cancer	3.46e-05	0.000284	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CASP3—liver cancer	3.43e-05	0.000282	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL2—liver cancer	3.43e-05	0.000281	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CG—liver cancer	3.41e-05	0.00028	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—IL6—liver cancer	3.41e-05	0.00028	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CCND1—liver cancer	3.34e-05	0.000274	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—JUN—liver cancer	3.33e-05	0.000274	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CTNNB1—liver cancer	3.31e-05	0.000272	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PPARG—liver cancer	3.3e-05	0.000271	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MMP9—liver cancer	3.24e-05	0.000266	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—CDKN1A—liver cancer	3.23e-05	0.000265	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MAPK8—liver cancer	3.15e-05	0.000259	CbGpPWpGaD
Olmesartan—AGTR1—Signaling by GPCR—AKT1—liver cancer	3.15e-05	0.000258	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CD—liver cancer	3e-05	0.000246	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—ALB—liver cancer	2.96e-05	0.000243	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—VEGFA—liver cancer	2.91e-05	0.000239	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—STAT3—liver cancer	2.88e-05	0.000237	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—MYC—liver cancer	2.68e-05	0.00022	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TGFB1—liver cancer	2.67e-05	0.000219	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CB—liver cancer	2.62e-05	0.000215	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—KRAS—liver cancer	2.48e-05	0.000203	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—PIK3CA—liver cancer	2.37e-05	0.000195	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—PIK3CA—liver cancer	2.28e-05	0.000187	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—TP53—liver cancer	2.2e-05	0.000181	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—HRAS—liver cancer	2.1e-05	0.000173	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—IL6—liver cancer	2.01e-05	0.000165	CbGpPWpGaD
Olmesartan—SLCO1B3—Metabolism—AKT1—liver cancer	1.94e-05	0.000159	CbGpPWpGaD
Olmesartan—AGTR1—Signaling Pathways—AKT1—liver cancer	1.86e-05	0.000153	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—PIK3CA—liver cancer	1.6e-05	0.000131	CbGpPWpGaD
Olmesartan—SLCO1B1—Metabolism—AKT1—liver cancer	1.3e-05	0.000107	CbGpPWpGaD
